Hüsnü PULLUKÇU, Şöhret AYDEMİR, Meltem İşikgöz TAŞBAKAN, Oğuz Reşat SİPAHİ, Feriha Çilli Hall JR, Alper TÜNGER

Is there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004 – 2011

Resistance patterns of Escherichia coli to fosfomycin, ciprofloxacin, amikacin, and cotrimoxazole were evaluated in 2 different studies held in 2004 and 2005. In this study, it was aimed to compare the changes in the susceptibility patterns of uropathogenic E. coli strains to the above-mentioned antibiotics after 6 years. Materials and methods: Between February and April 2011, E. coli strains isolated from urine samples were included prospectively in the study. Results: A total of 502 E. coli strains (358 from outpatients and 144 from inpatients) were isolated from urine specimens between February and April 2011. Extended spectrum beta-lactamase (ESBL)-producer E. coli rate was 35%. Resistances to cotrimoxazole, ciprofloxacin, amikacin, and fosfomycin were 54.5%, 49.8%, 22.7%, and 1.4%, respectively. When we compared ESBL-producer E. coli strains isolated in 2005 and 2011, amikacin resistance increased (11% to 22.7%, P = 0.0001), whereas cotrimoxazole resistance decreased significantly (74% to 62.9%, P = 0.0063). When we compared resistance patterns of non-ESBL-producer E. coli in relation to 2004 and 2011, there was no significant change in the resistance to fosfomycin, cotrimoxazole, ciprofloxacin, and amikacin. Pooled analysis of fosfomycin studies from Turkey revealed 1.6% fosfomycin resistance in a total of 6439 strains. Conclusion: Our results suggest that despite common usage, there is not an increase in the resistance to fosfomycin. We conclude that fosfomycin can be used as one of the primary choices in the empirical therapy of urinary tract infections.

Anahtar Kelimeler:

Key words: Resistance, fosfomycin, urinary tract infection

Is there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004 – 2011

Keywords:

Key words: Resistance, fosfomycin, urinary tract infection,

PDF

___

Coşkun Ö, Erdem H, Avcı A. Management of communityacquired acute bacterial cystitis in Turkey. Turk J Med Sci 2011; 41: 149–57.
Pullukçu H, Aydemir Ş, Taşbakan MI, Çilli F, Tunger A, Ulusoy S. Susceptibility of extended-spectrum beta-lactamase producing Esherichia coli urine isolates to fosfomycin, ciprofloxacin, amikacin and trimethoprim sulfamethoxazole. Turk J Med Sci 2008; 38: 175–80.
Taşbakan MI, Pullukçu H, Yamazhan T, Arda B, Ulusoy S. Toplum kökenli üriner sistem infeksiyonlarından soyutlanan Escherichia coli suşlarına fosfomisinin in-vitro etkinliğinin diğer antibiyotiklerle karşılaştırılması. ANKEM Derg 2004; 18: 216–9 (in Turkish).
Pullukçu H, Taşbakan M, Sipahi OR, Yamazhan T, Aydemir Ş, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli related lower urinary tract infections. Int J Antimicrob Agents 2007; 29: 62–
Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamaseproducing Escherichia coli-related complicated lower urinary tract infection. J Chemother 2010; 22: 355–7.
Clinical and Laboratory Standards Institute. 2011 Antimicrobial Susceptibility Testing Update. Wayne, PA, USA: CLSI; 2011. Available at http://www.clsi.org/Content/NavigationMenu/ Education/Teleconferences/Feb232011.htm.
Yaşar KK, Pehlivanoğlu F, Şengöz G. Alternatif tedavi seçeneği olraka fosfomisinin komplike üriner sistem infeksiyonlarından izole edilejn GSBL pozitif Escherichia coli suşlarına etkinliği. ANKEM Derg 2011; 25: 12–6 (in Turkish).
Mengeloğlu FZ, Demircan F, Oduncu MK. İdrar kültürlerinden soyutlanan Escherichia coli izolatlarının fosfomisine karşı invitro duyarlılıklarının değerlendirilmesi. ANKEM Derg 2011; 25: 99–102 (in Turkish).
Bayram Y, Eren H, Berktaş M. İdrar örneklerinden izole edilen bakteriyel patojenlerin dağılımı ve GSBL pozitif ve negatif Escherichia coli suşlarının fosfomisin ve diğer antimikrobiyallere duyarlılık paterni. ANKEM Derg 2011; 25: 232–6 (in Turkish).
Deveci Ö, Yula E, Özer TT, Tekin A. Üriner sistem infeksiyonlarından izole edilen Escherichia coli suşlarına fosfomisin trometamolün ve bazı antibiyotiklerin in-vitro etkinliği. Dicle Tıp Dergisi 2011; 38: 298–300 (in Turkish).
Ceran N, Mert D, Koçdoğan FY, Erdem I, Adalati R, Ozyurek S et al. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother 2010; 16: 424–30.
Hoşbul T, Ozyurt M, Baylan O, Bektöre B, Ardiç N, Ceylan S et al. In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections. Mikrobiyol Bul 2009; 43: 645–9.
Uyanık H, Hancı H, Yazgı. Üriner sistem infeksiyonlarından soyutlanan toplum kökenli Escherichia coli suşlarına fosfomisin trometamolün ve bazı antibiyotiklerin in-vitro etkinliği. ANKEM Derg 2009; 23: 172–6 (in Turkish).
Aşık G, Çiftçi İH, Aktepe OC, Çetinkaya Z, Altındiş M. In vitro activity of fosfomycin against extended spectrum-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae strains. Turk J Immunol 2008; 13: 1–4.
Akyar I. Antibiotic resistance rates of extended spectrum betalactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital. Mikrobiyol Bul 2008; 42: 713–5.
Tekin A, Deveci Ö, Dal T, Tekin R, Özekinci T, Dayan S. Üropatojen Escherichia coli izolatlarına fosfomisin ve bazı antibiyotiklerin in vitro etkinliği. ANKEM Derg 2012; 26: 61–8 (in Turkish).
Pullukçu H, Aydemir Ş, Işıkgöz Taşbakan M, Sipahi OR, Çilli F, Ulusoy S. In vitro efficacy of nitrofurantoin on Escherichia coli strains isolated from urine cultures. Turk J Infect 2007; 21: 197–200.
Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended spectrum B-lactamase-producing Escherichia coli related lower urinary tract infection. Int J Antimicrob Agents 2012; 40: 554–56.
Arman D, Ağalar C, Dibay M, Tunçcan ÖG, Keten DT, Aygün G et al. Community acquired lower urinary tract infections in primary care: causative agents and antimicrobial susceptibility. J Infect Microb Antimicrob 2012; 1: 10.
Işıkgöz Taşbakan M, Pullukçu H, Sipahi OR, Yamazhan T, Arda B, Ulusoy S. A pooled analysis of the resistance patterns of Escherichia coli strains isolated from urine cultures in Turkey: a comparison of the periods 1997-2001 and 2002-2007. Turk J Med Sci 2011; 41: 557–64.
Özcan L, Yılmaz S, Pekdemir M, Yaka E. Akut nonkomplike Alt üriner sistem enfeksiyonu olan hastalarda fosfomisintrometamol ve siprofloksasinin etkinliğinin karşılaştırılması. Tr J Emerg Med 2011; 11: 104–9 (in Turkish).
Baylan O. Fosfomycin: past, present and future. Mikrobiyol Bul 2010; 44: 311–21.
Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 2012; 67: 255–68. safe remedy that continues to hold its ranking among the first treatment choices of both empirical and causative agent-based treatment of UTIs.